Skip to main content

Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 25, 2024.

via HealthDay

WEDNESDAY, Sept. 25, 2024 -- For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and a reduction in flares, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.

Daniel Lyons, M.D., from St. Vincent's University Hospital in Dublin, and colleagues reported the impact of semaglutide on disease control and quality of life among 30 patients with obesity (27 female and three male) from an HS clinic.

All of the patients were prescribed concomitant HS treatments. The researchers found that the mean duration of semaglutide treatment was 8.2 months and the mean dose was 0.8 mg once weekly. There was a decrease seen in mean body mass index, from 43.1 to 41.5 kg/m2. In addition, the mean weight decreased from 117.7 to 111.6 kg. Overall, 33.33 percent of the patients lost ≥10 kg during the study period. The mean frequency of patient-reported flares decreased from once every 8.5 weeks to once every 12 weeks following commencement of semaglutide, with a reduction in the mean Dermatology Life Quality Index (DLQI) from 13/30 to 9/30. A DLQI reduction of 4 points or more, equal to or surpassing the minimal clinically important difference, occurred in one-third of patients. There was also a significant reduction in hemoglobin A1c (from 39.3 to 36.6).

"We hope our preliminary data will encourage dermatologists to consider weight loss medication as an adjunct to existing HS treatments," Lyons said in a statement.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Prevalence of Extremely Severe Obesity Increasing in Children

TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...

Long-Term Obesity Linked to Expression of Aging Biomarkers

THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...

ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide

THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.